Chevy Chase Trust Holdings LLC Lowers Position in Edwards Lifesciences Corporation $EW

Chevy Chase Trust Holdings LLC trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 304,841 shares of the medical research company’s stock after selling 10,226 shares during the quarter. Chevy Chase Trust Holdings LLC owned approximately 0.05% of Edwards Lifesciences worth $23,707,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in EW. Level Four Advisory Services LLC lifted its stake in shares of Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company’s stock valued at $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC grew its stake in Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company’s stock worth $2,504,000 after purchasing an additional 120 shares during the period. Howard Capital Management Inc. raised its holdings in Edwards Lifesciences by 3.3% in the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company’s stock worth $322,000 after purchasing an additional 132 shares in the last quarter. Empirical Finance LLC raised its holdings in Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares in the last quarter. Finally, Alpine Bank Wealth Management lifted its position in Edwards Lifesciences by 10.7% during the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock valued at $108,000 after buying an additional 135 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on EW shares. Canaccord Genuity Group set a $87.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Wednesday, December 17th. Citigroup reissued a “buy” rating and set a $101.00 price objective (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Royal Bank Of Canada upped their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Finally, Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the stock a “buy” rating in a research report on Tuesday, January 20th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $83.59 on Tuesday. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The company’s 50-day moving average is $82.40 and its 200 day moving average is $81.60. The company has a market capitalization of $48.55 billion, a price-to-earnings ratio of 45.68, a price-to-earnings-growth ratio of 2.13 and a beta of 0.93. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $85.93, for a total transaction of $974,446.20. Following the sale, the vice president directly owned 21,266 shares in the company, valued at approximately $1,827,387.38. This trade represents a 34.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total value of $1,103,960.00. Following the completion of the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 61,718 shares of company stock valued at $5,236,281 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.